--- title: "Orforglipron | PepTracker Pro" url: https://peptrackerpro.com/peptides/orforglipron description: "The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. Aliases Foundayo +1 more Evidence High Evidence Last Updated 2026-07-15 Reading Time 5 min ## What It Is Orforglipron (brand name Foundayo) is a once-daily oral small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 drugs and oral semaglutide, orforglipron is a non-peptide molecule that can be taken any time of day without food or water restrictions. It received FDA approval on April 1, 2026 — the fastest new molecular entity approval since 2002, completed in just 50 days under the Commissioner's National Priority Voucher program. Foundayo prescriptions began shipping April 6, 2026, via LillyDirect, with broad U.S. retail pharmacy and telehealth availability following shortly after. The Phase 3 ATTAIN program demonstrated dose-dependent weight loss of 7.5% to 11.2% at 72 weeks in adults with obesity without diabetes (ATTAIN-1), and 5.1% to 9.6% in adults with obesity and type 2 diabetes (ATTAIN-2). A population-adjusted indirect treatment comparison presented at Obesity Medicine Association 2026 found that oral Wegovy (semaglutide 25 mg) demonstrated significantly greater mean weight loss than orforglipron 36 mg based on OASIS 4 vs ATTAIN-1 data, though orforglipron's no-restriction dosing convenience remains a differentiator. Foundayo is included in the Medicare GLP-1 Bridge program launching July 1, 2026, available to eligible Part D beneficiaries for a $50 copayment. Orforglipron represents a significant advance in accessibility for GLP-1 therapy, removing the need for injections entirely. In a head-to-head comparison, orforglipron 36 mg lowered A1C by 2.2% compared with 1.4% for oral semaglutide 14 mg, and patients who received orforglipron 36 mg lost 19.7 pounds compared with 11.0 pounds with oral semaglutide 14 mg — demonstrating superiority over the first-generation oral GLP-1 in glycemic and weight endpoints. The ATTAIN-Maintain Phase 3 trial demonstrated that oral orforglipron can effectively preserve weight loss achieved with injectable GLP-1 therapies. In a 52-week study, patients who switched from injectable semaglutide (Wegovy) to orforglipron maintained their weight loss with an average difference of only 0.9 kg, while those switching from tirzepatide (Zepbound) maintained with a 5.0 kg average difference — establishing orforglipron as a viable oral maintenance option after injectable-initiated weight loss. In May 2026, Eli Lilly announced the third successful Phase 3 trial of orforglipron for obesity, triggering global regulatory submissions for the weight management indication this year. This trial broadens the evidence base across diverse patient populations. An NIH-funded study published in Nature (2026) revealed a new mechanism by which oral small-molecule GLP-1 drugs suppress hedonic feeding (eating for pleasure). Researchers at the University of Virginia found that small-molecule GLP-1 agonists penetrate deep into the brain to activate the central amygdala — a region associated with desire that was not previously known to be directly reachable by GLP-1 drugs. Once activated, the central amygdala reduces dopamine release into the brain's reward circuitry during pleasure-driven eating. This pathway is separate from previously described appetite-suppression mechanisms and may explain emerging observations that GLP-1 drugs reduce addictive behaviors beyond food, including substance use disorders. The competitive landscape for oral GLP-1 therapies intensified in May 2026 with the nationwide launch of Ozempic tablets (oral semaglutide) at prices starting from $149/month and aleniglipron's ACCESS II 44-week data showing 16.3% weight loss — the highest efficacy for any oral GLP-1 RA. Orforglipron's differentiation rests on its non-peptide small-molecule structure, once-daily dosing without food restrictions, and established Phase 3 dataset. Post-hoc analyses from the ATTAIN-1 and ATTAIN-2 trials presented at ADA 2026 (June 8) demonstrated that Foundayo delivers significant weight loss at every stage of menopause: in ATTAIN-1, peri-menopausal women lost up to 30.4 lbs (14.4%) at the highest dose, with 51.5% achieving ≥15% weight loss. ACHIEVE Phase 3 T2D data also presented at ADA 2026 confirmed orforglipron as superior to dapagliflozin (ACHIEVE-2: A1C −1.7% vs −0.8%) and effective as an add-on to insulin glargine (ACHIEVE-5: A1C −2.1% vs −0.8% placebo), establishing the full T2D prescribing profile ahead of the expected T2D indication approval. Also known as: Foundayo, LY3502970 ## Regulatory Status FDA-Approved Approved April 1, 2026 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Prescription required. Effective: April 2026 View FDA Source (https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program) ## Why Researchers Study It Orforglipron is significant as the first oral non-peptide GLP-1 agonist to reach market. Its small-molecule design solves key limitations of peptide-based GLP-1 drugs: it doesn't require injection, has no food or water timing restrictions, and is stable at room temperature. This opens GLP-1 therapy to patients who are needle-averse or have difficulty with dosing restrictions. ## Proposed Mechanisms - Selectively activates GLP-1 receptors in the hypothalamus to reduce appetite - Slows gastric emptying to prolong satiety after meals - Stimulates glucose-dependent insulin secretion from pancreatic beta cells - Small-molecule design provides oral bioavailability without permeation enhancers - Does not require fasting or water restrictions due to non-peptide structure ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 3) | ATTAIN-1: Adults with obesity, no T2D (n=3,127) | 7.5%–11.2% weight loss at 72 weeks vs 2.1% placebo | Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 | | Human (Phase 3) | ATTAIN-2: Adults with obesity + T2D (n=1,600+) | 5.1%–9.6% weight loss at 72 weeks vs 2.5% placebo; improved HbA1c | Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02165-8/abstract | | Human (Phase 2) | Adults with obesity (NEJM 2023) | Up to 14.7% weight loss at 36 weeks in dose-finding study | Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2302392 | | Human (Phase 3, ATTAIN-Maintain) | Switch from injectable GLP-1 to oral orforglipron, 52 weeks | Maintained weight loss after switching from Wegovy (0.9 kg difference) or Zepbound (5.0 kg difference) | Source: https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after | | Human (Phase 3, ACHIEVE-3) | Head-to-head vs oral semaglutide 14 mg in T2D (Lancet 2026) | Orforglipron 36 mg lowered A1C by 2.2% vs 1.4% for oral semaglutide; weight loss of 19.7 lbs vs 11.0 lbs — demonstrating superiority | Source: https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar | | Human (Phase 3, ATTAIN-2, Lancet 2026) | Adults with obesity + T2D (n=1,600+), 72 weeks, published in The Lancet | 10.5% weight loss (22.9 lbs) on 36 mg dose; HbA1c reduced by 1.8% | Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02165-8/abstract | | Preclinical (Nature 2026) | Oral small-molecule GLP-1 agonists in mice (hedonic feeding paradigm) | GLP-1 agonists activate central amygdala, reducing dopamine release in reward circuitry; suppresses eating for pleasure via distinct pathway from appetite suppression | Source: https://www.nih.gov/news-events/news-releases/oral-small-molecule-glp-1-drugs-penetrate-deep-into-brain-suppress-cravings | | Human (Phase 3, ATTAIN-1 sub-analysis) | Women with obesity at pre-, peri-, and post-menopause (n=1,500+ female participants from ATTAIN-1) | Weight loss of 28.0 lbs (12.8%), 30.4 lbs (14.4%), and 28.2 lbs (14.1%) for pre-, peri-, and post-menopausal women respectively at highest dose; 51.5% achieved ≥15% weight loss | Source: https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-only-oral-glp-1-taken-without-food | | Human (Phase 3, ATTAIN-2 sub-analysis) | Women with obesity + T2D at every menopausal stage (from ATTAIN-2) | Weight loss of 23.4 lbs (11.3%), 18.5 lbs (8.9%), and 27.8 lbs (13.6%) for pre-, peri-, and post-menopausal women; up to 44.2% achieved ≥15% weight loss | Source: https://www.hcplive.com/view/orforglipron-delivers-significant-weight-loss-at-every-stage-of-menopause-in-phase-3-attain-trials | | Human (Phase 3, ACHIEVE-2) | Adults with T2D (ACHIEVE-2: orforglipron vs dapagliflozin), 40 weeks | A1C lowered by up to 1.7% vs 0.8% with dapagliflozin; orforglipron met primary endpoint | Source: https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-foundayo-mounjaro-and-retatrutide | | Human (Phase 3, ACHIEVE-5) | Adults with T2D on insulin glargine (ACHIEVE-5: orforglipron + insulin vs placebo + insulin), 40 weeks | A1C lowered by up to 2.1% vs 0.8% with placebo when combined with titrated insulin glargine | Source: https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-foundayo-mounjaro-and-retatrutide | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Mood: https://peptrackerpro.com/benefits/mood Researching Orforglipron? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=orforglipron) ## Safety & Cautions - FDA-approved for chronic weight management only (not diabetes as of May 2026); T2D indication under review following successful ACHIEVE-3 trial showing superiority over oral semaglutide - Gastrointestinal side effects (nausea, vomiting, diarrhea) are common, especially during dose escalation - Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 - Weight loss is less than injectable semaglutide 2.4 mg or oral Wegovy 25 mg; appropriate for patients valuing dosing convenience - Additional indications (T2D, sleep apnea, PAD) still under investigation ## Comparisons See how Orforglipron compares to related peptides: Orforglipron vs Avexitide: https://peptrackerpro.com/compare/orforglipron-vs-avexitide Orforglipron vs Cagrilintide: https://peptrackerpro.com/compare/orforglipron-vs-cagrilintide Orforglipron vs Conveglipron: https://peptrackerpro.com/compare/orforglipron-vs-conveglipron Orforglipron vs CX11: https://peptrackerpro.com/compare/orforglipron-vs-cx11 Orforglipron vs Efpeglenatide: https://peptrackerpro.com/compare/orforglipron-vs-efpeglenatide Orforglipron vs Elecoglipron: https://peptrackerpro.com/compare/orforglipron-vs-elecoglipron Orforglipron vs Enlicitide: https://peptrackerpro.com/compare/orforglipron-vs-enlicitide Orforglipron vs KAI-7535: https://peptrackerpro.com/compare/orforglipron-vs-kai-7535 Orforglipron vs Maridebart Cafraglutide (MariTide): https://peptrackerpro.com/compare/orforglipron-vs-maridebart-cafraglutide Orforglipron vs MET-097i: https://peptrackerpro.com/compare/orforglipron-vs-met-097i Orforglipron vs Retatrutide: https://peptrackerpro.com/compare/orforglipron-vs-retatrutide Orforglipron vs Semaglutide: https://peptrackerpro.com/compare/orforglipron-vs-semaglutide Orforglipron vs Survodutide: https://peptrackerpro.com/compare/orforglipron-vs-survodutide Orforglipron vs Tirzepatide: https://peptrackerpro.com/compare/orforglipron-vs-tirzepatide Orforglipron vs HRS9531 (KAI-9531): https://peptrackerpro.com/compare/orforglipron-vs-hrs9531 ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] FDA Approves Foundayo (orforglipron) — FDA Press Release, April 2026 PubMed (https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program) 2. [2] Eli Lilly — Foundayo FDA Approval Announcement, April 2026 PubMed (https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill) 3. [3] Orforglipron Phase 2 results — NEJM 2023 PubMed (https://www.nejm.org/doi/full/10.1056/NEJMoa2511774) 4. [4] Wegovy pill vs orforglipron indirect comparison — Obesity Medicine Association 2026 PubMed (https://www.prnewswire.com/news-releases/wegovy-pill-demonstrated-greater-weight-loss-than-orforglipron-302732768.html) 5. [5] ATTAIN-Maintain: Orforglipron maintains weight loss after injectable GLP-1 switch — Eli Lilly 2026 PubMed (https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after) 6. [6] NIH — Oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings. Nature 2026 PubMed (https://www.nih.gov/news-events/news-releases/oral-small-molecule-glp-1-drugs-penetrate-deep-into-brain-suppress-cravings) 7. [7] Eli Lilly — ACHIEVE-3: Orforglipron superiority vs oral semaglutide in T2D (Lancet 2026) PubMed (https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar) 8. [8] Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity with T2D (ATTAIN-2) — The Lancet 2026 PubMed (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02165-8/abstract) 9. [9] Eli Lilly — Foundayo Delivers Significant Weight Loss at Every Stage of Menopause (ADA 2026) PubMed (https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-only-oral-glp-1-taken-without-food) 10. [10] HCPLive — Orforglipron Delivers Weight Loss at Every Menopausal Stage in Phase 3 ATTAIN Trials (ADA 2026) PubMed (https://www.hcplive.com/view/orforglipron-delivers-significant-weight-loss-at-every-stage-of-menopause-in-phase-3-attain-trials) 11. [11] Eli Lilly — New ACHIEVE Data (ACHIEVE-2, ACHIEVE-3, ACHIEVE-5) for Foundayo in T2D at ADA 2026 PubMed (https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-foundayo-mounjaro-and-retatrutide) ### Keep researching in the app - Log Orforglipron to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=orforglipron Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Avexitide Medium Evidence A first-in-class once-daily injectable GLP-1 receptor ANTAGONIST (exendin 9-39) from Amylyx for hyperinsulinemic hypoglycemia. The mirror image of GLP-1 agonists like semaglutide, it blocks GLP-1 to stop the insulin surges that cause post-bariatric hypoglycemia. Phase 3 LUCIDITY completed enrollment March 2026 with topline data expected Q3 2026. Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Metabolism: https://peptrackerpro.com/benefits/metabolism Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/avexitide \+ Compare: https://peptrackerpro.com/compare?select=avexitide Track in App: https://app.peptrackerpro.com/?add=avexitide ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### Conveglipron Low Evidence An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/conveglipron \+ Compare: https://peptrackerpro.com/compare?select=conveglipron Track in App: https://app.peptrackerpro.com/?add=conveglipron ### CX11 Medium Evidence CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/cx11 \+ Compare: https://peptrackerpro.com/compare?select=cx11 Track in App: https://app.peptrackerpro.com/?add=cx11 ### Efpeglenatide High Evidence A once-weekly, long-acting GLP-1 receptor agonist from Hanmi Pharmaceutical built on a different molecular backbone than semaglutide or liraglutide: instead of a modified human GLP-1, efpeglenatide uses exendin-4 - the naturally DPP-4-resistant GLP-1 mimic first found in Gila monster venom - fused to a fragment of a human antibody (an IgG4 Fc) through a small polyethylene-glycol (mini-PEG) linker using Hanmi's LAPSCOVERY half-life-extension platform. That design lets one subcutaneous injection lower blood sugar, curb appetite and reduce body weight for a full week. Efpeglenatide is best known for the landmark AMPLITUDE-O cardiovascular outcomes trial (NEJM 2021), in which 4,076 people with type 2 diabetes and cardiovascular or kidney disease had a 27% lower rate of major adverse cardiovascular events (MACE hazard ratio 0.73) and a 32% lower rate of a composite kidney outcome (hazard ratio 0.68) versus placebo - the first cardiovascular outcomes win for an exendin-based GLP-1 and one of the clearest kidney signals in the class, with benefit seen regardless of whether patients were also taking an SGLT2 inhibitor. Originally licensed to Sanofi and then returned to Hanmi in 2020, efpeglenatide is now being advanced primarily for obesity and overweight, with a Phase 3 program that has completed enrollment and a targeted first launch in South Korea in the second half of 2026. It is an investigational (not yet approved) prescription medicine, not a supplement or research chemical. Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health View Details: https://peptrackerpro.com/peptides/efpeglenatide \+ Compare: https://peptrackerpro.com/compare?select=efpeglenatide Track in App: https://app.peptrackerpro.com/?add=efpeglenatide ### Elecoglipron Medium Evidence An investigational, once-daily oral small-molecule GLP-1 receptor agonist from AstraZeneca that delivered up to about 11.8% weight loss at 36 weeks in people with obesity or overweight and strong blood-sugar control in type 2 diabetes, and is now advancing into a large Phase 3 program. Unlike semaglutide and tirzepatide - which are injectable peptides - elecoglipron is a small chemical molecule that mimics the natural GLP-1 hormone at its receptor in the gut and hypothalamus, so it can be taken as a pill with no food or fasting restrictions and is easier and cheaper to manufacture at global scale than peptide drugs. In the Phase 2b VISTA trial (n=310) the 75 mg once-daily regimen produced an average body-weight reduction of 10.5% at 26 weeks (vs 0.6% placebo) that had not plateaued, reaching about 11.8% at 36 weeks, with up to 88.8% of participants achieving at least 5% weight loss. In the Phase 2b SOLSTICE trial in type 2 diabetes (n=404) the 75 mg regimen cut HbA1c by 1.9% at 26 weeks (vs 0.2% placebo) - with roughly 90% of participants reaching an HbA1c below 7% - alongside 7.7% weight loss, numerically ahead of an open-label oral semaglutide 14 mg comparator arm. Side effects were the familiar GLP-1 class gastrointestinal symptoms (nausea, constipation, diarrhea, vomiting), mostly mild to moderate, with infrequent discontinuations and no liver safety signals. Both trials were presented at the 2026 American Diabetes Association (ADA) Scientific Sessions in New Orleans and published simultaneously in The Lancet, and on June 8, 2026 AstraZeneca announced elecoglipron would move into an extensive Phase 3 program - the EMBOLD obesity trials and the ELUMINATE type 2 diabetes trials (including combination with dapagliflozin), plus cardiovascular and kidney outcome studies. Elecoglipron is an investigational prescription-stage medicine - it is not approved anywhere and is not a supplement or research chemical. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Glycemic Control (https://peptrackerpro.com/benefits/glycemic-control)+1 more View Details: https://peptrackerpro.com/peptides/elecoglipron \+ Compare: https://peptrackerpro.com/compare?select=elecoglipron Track in App: https://app.peptrackerpro.com/?add=elecoglipron ### Enlicitide High Evidence An oral PCSK9 inhibitor peptide that reduced LDL cholesterol by 57% in Phase 3 trials — matching injectable monoclonal antibodies in efficacy while offering once-daily pill convenience. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/enlicitide \+ Compare: https://peptrackerpro.com/compare?select=enlicitide Track in App: https://app.peptrackerpro.com/?add=enlicitide ### KAI-7535 Medium Evidence An oral once-daily small-molecule GLP-1 receptor agonist (Hengrui's HRS-7535, licensed to Kailera) that delivered up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and met its Phase 3 diabetes endpoint, now in a global Phase 2 dose-optimization study. View Details: https://peptrackerpro.com/peptides/kai-7535 \+ Compare: https://peptrackerpro.com/compare?select=kai-7535 Track in App: https://app.peptrackerpro.com/?add=kai-7535 ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### MET-097i Medium Evidence An ultra-long-acting GLP-1 receptor agonist designed for both once-weekly and once-monthly subcutaneous dosing, delivering double-digit weight loss with class-leading gastrointestinal tolerability in mid-stage trials. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/met-097i \+ Compare: https://peptrackerpro.com/compare?select=met-097i Track in App: https://app.peptrackerpro.com/?add=met-097i ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/retatrutide \+ Compare: https://peptrackerpro.com/compare?select=retatrutide Track in App: https://app.peptrackerpro.com/?add=retatrutide ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. View Details: https://peptrackerpro.com/peptides/survodutide \+ Compare: https://peptrackerpro.com/compare?select=survodutide Track in App: https://app.peptrackerpro.com/?add=survodutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ### HRS9531 (KAI-9531) Medium Evidence An investigational once-weekly injectable dual GLP-1/GIP receptor agonist - the same peptide class as tirzepatide (Zepbound/Mounjaro) - developed by China's Jiangsu Hengrui Pharmaceuticals as HRS9531 and licensed to U.S.-based Kailera Therapeutics, which is developing it globally (outside Greater China) as KAI-9531. In the pivotal 48-week Phase 3 GEMINI-1 trial in China (NCT06396429; 567 adults with obesity or overweight without diabetes), once-weekly HRS9531 produced mean weight loss of about 17.4-19.2% at the 4 mg and 6 mg doses (per-protocol/hypothetical estimand) versus roughly 1.4% for placebo, with about 44% of 6 mg patients losing at least 20% of body weight and broad improvements in blood pressure, lipids, insulin resistance, and inflammation (hsCRP). An earlier Phase 2 trial reported about 23.6% mean weight loss at the higher 8 mg dose by week 36 with no plateau. Hengrui has submitted a marketing application to China's NMPA for chronic weight management, and Kailera began a global Phase 3 program (KAI-9531) evaluating higher maintenance doses (8 mg and 10 mg) and longer treatment by late 2025. HRS9531/KAI-9531 is investigational, is not approved outside of any regulatory review in China, and is not a supplement or research chemical; it is studied only in clinical trials. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/hrs9531 \+ Compare: https://peptrackerpro.com/compare?select=hrs9531 Track in App: https://app.peptrackerpro.com/?add=hrs9531 ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Orforglipron", "description": "The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions.", "url": "https://peptrackerpro.com/peptides/orforglipron", "lastReviewed": "2026-07-15", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Orforglipron", "item": "https://peptrackerpro.com/peptides/orforglipron" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People seeking an oral alternative to injectable GLP-1 medications?", "acceptedAnswer": { "@type": "Answer", "text": "Orforglipron is a research peptide studied in preclinical models. The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions." } }, { "@type": "Question", "name": "Those comparing weight management options without injection?", "acceptedAnswer": { "@type": "Answer", "text": "Orforglipron is a research peptide studied in preclinical models. The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions." } }, { "@type": "Question", "name": "Healthcare providers evaluating new FDA-approved obesity treatments?", "acceptedAnswer": { "@type": "Answer", "text": "Orforglipron is a research peptide studied in preclinical models. The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions." } }, { "@type": "Question", "name": "Individuals interested in the latest GLP-1 receptor agonist developments?", "acceptedAnswer": { "@type": "Answer", "text": "Orforglipron is a research peptide studied in preclinical models. The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions." } } ] } ] ```